프로티아

303360KOSDAQ

56.0 / 100

Reference Date: 2026-10-23

Financial Score31.5 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Plunged 29.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

ProTia develops, manufactures, and sells in vitro diagnostic medical devices based on immune diagnostic technology, specializing in allergy, food intolerance, and antibiotic susceptibility tests. The company holds over 45% market share domestically and has expanded to 68 countries globally. It continuously innovates through its in-house research institute, earning three Yangsil Awards and four NET technology certifications from the government.

Number of Employees

113people

Average Salary

41.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

10.55Industry Average 15.006.5Point

Lower than industry avg (good)

PBR

1.54Industry Average 1.202.5Point

Higher than industry avg (caution)

ROE

15.72Industry Average 8.005.5Point

2.0x industry avg (good)

Debt Ratio

1.33Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20259.0 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲35.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲481.5% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 9.3% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 3,660Won52-week high 6,55052-week low 3,660

1-month return0.0Point

1m -29.21% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral권리락 (무상증자)2026-10-12
Neutral주요사항보고서(무상증자결정)2026-09-29
Neutral주권매매거래정지 (무상증자)2026-09-29
Neutral주주명부폐쇄기간또는기준일설정2026-09-29